Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$18.34
+3.0%
$19.88
$10.21
$25.67
$4.25B0.433.67 million shs1.82 million shs
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$60.08
+9.6%
$41.72
$30.04
$63.68
$4.73B1.821.92 million shs5.33 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$31.39
+4.2%
$24.06
$16.16
$31.53
$1.22B0.75218,752 shs469,142 shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$35.78
+6.9%
$33.28
$27.66
$121.06
$4.32B1.191.48 million shs2.01 million shs
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
+2.98%+1.10%-12.12%-1.82%+53.34%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
+9.60%+16.28%+42.74%+75.36%+9.18%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
+4.22%+12.35%+29.55%+77.14%+83.14%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
+6.93%+7.54%-3.82%+27.60%-55.79%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
4.1359 of 5 stars
3.72.00.00.02.92.53.1
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.9834 of 5 stars
4.31.00.00.01.92.50.6
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
3.6762 of 5 stars
0.92.02.51.13.03.32.5
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
1.7513 of 5 stars
3.61.00.00.02.01.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
3.33
Buy$27.6750.85% Upside
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.53
Moderate Buy$71.7519.42% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.83
Reduce$24.40-22.27% Downside
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10
Buy$136.50281.50% Upside

Current Analyst Ratings Breakdown

Latest PAHC, CRSP, ADMA, and PCVX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$81.00
7/7/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Overweight$25.00 ➝ $35.00
6/27/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$105.00
6/27/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$86.00
6/27/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$65.00
6/26/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$81.00
6/26/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$82.00
6/25/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetEqual Weight ➝ Equal Weight$21.00 ➝ $26.00
6/16/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
6/16/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
BNP Paribas Exane
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Neutral$24.00
5/21/2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$86.00 ➝ $86.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$426.45M10.27$0.56 per share32.90$1.48 per share12.39
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$37.31M139.06N/AN/A$22.64 per share2.65
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.02B1.25$2.20 per share14.25$6.34 per share4.95
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/A$26.52 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$197.67M$0.8521.5826.58N/A45.01%47.16%30.51%8/6/2025 (Estimated)
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$366.25M-$4.52N/AN/AN/A-1,023.64%-20.08%-17.13%8/4/2025 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$2.42M$0.7840.2414.950.502.68%30.51%6.89%8/27/2025 (Estimated)
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$463.93M-$3.99N/AN/AN/AN/A-17.12%-16.26%8/5/2025 (Estimated)

Latest PAHC, CRSP, ADMA, and PCVX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.12N/AN/AN/AN/AN/A
8/4/2025Q2 2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.54N/AN/AN/A$6.44 millionN/A
5/14/2025Q1 2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.02-$1.04-$0.02-$1.04N/AN/A
5/7/2025Q1 2025
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
$0.16$0.14-$0.02$0.11$116.40 million$114.80 million
5/7/2025Q3 2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.52$0.63+$0.11$0.51$352.41 million$347.80 million
5/6/2025Q1 2025
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.27-$1.58-$0.31-$1.58N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
N/AN/AN/AN/AN/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.53%N/A61.54%N/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/AN/A

Latest PAHC, CRSP, ADMA, and PCVX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.122.52%6/4/20256/4/20256/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
0.22
6.58
3.36
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/A
15.64
15.64
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.67
2.91
1.23
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/A
17.70
17.70

Institutional Ownership

CompanyInstitutional Ownership
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
75.68%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
96.78%

Insider Ownership

CompanyInsider Ownership
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
3.50%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
4.30%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
50.07%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
ADMA Biologics Inc stock logo
ADMA
ADMA Biologics
530238.73 million230.38 millionOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
46086.36 million82.65 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1,94040.53 million20.24 millionOptionable
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
160129.00 million125.01 millionOptionable

Recent News About These Companies

Vaxcyte: Sentiment Is Pushing The Shares Down
Vaxcyte appoints new independent director
TD Cowen Keeps Their Buy Rating on Vaxcyte (PCVX)

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADMA Biologics stock logo

ADMA Biologics NASDAQ:ADMA

$18.34 +0.53 (+2.98%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$18.42 +0.09 (+0.46%)
As of 04:44 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

CRISPR Therapeutics stock logo

CRISPR Therapeutics NASDAQ:CRSP

$60.08 +5.26 (+9.60%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$62.36 +2.28 (+3.79%)
As of 05:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$31.39 +1.27 (+4.22%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$31.00 -0.39 (-1.24%)
As of 07/9/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Vaxcyte stock logo

Vaxcyte NASDAQ:PCVX

$35.78 +2.32 (+6.93%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$35.68 -0.09 (-0.27%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.